4.7 Article

Activation of the DNA damage response in vivo in synucleinopathy models of Parkinson's disease

期刊

CELL DEATH & DISEASE
卷 9, 期 -, 页码 -

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/s41419-018-0848-7

关键词

-

资金

  1. Michael J. Fox Foundation
  2. Target Validation Grant
  3. Fondazione Umberto Veronesi Post-doctoral Fellowship

向作者/读者索取更多资源

The involvement of DNA damage and repair in aging processes is well established. Aging is an unequivocal risk factor for chronic neurodegenerative diseases, underscoring the relevance of investigations into the role that DNA alterations may have in the pathogenesis of these diseases. Consistently, even moderate impairment of DNA repair systems facilitates the onset of pathological features typical of PD that include derangement of the dopaminergic system, mitochondrial dysfunction, and alpha-synuclein stress. The latter establishes a connection between reduced DNA repair capacity and a cardinal feature of PD, alpha-synuclein pathology. It remains to be determined, however, whether alpha-synuclein stress activates in vivo the canonical signaling cascade associated with DNA damage, which is centered on the kinase ATM and substrates such as gamma H2Ax and 53BP1. Addressing these issues would shed light on age-related mechanisms impinging upon PD pathogenesis and neurodegeneration in particular. We analyzed two different synucleinopathy PD mouse models based either on intranigral delivery of AAV-expressing human alpha-synuclein, or intrastriatal injection of human alpha-synuclein pre-formed fibrils. In both cases, we detected a significant increase in gamma H2AX and 53BP1 foci, and in phospho-ATM immunoreactivity in dopaminergic neurons, which collectively indicate DNA damage and activation of the DNA damage response. Mechanistic experiments in cell cultures indicate that activation of the DNA damage response is caused, at least in part, by pro-oxidant species because it is prevented by exogenous or endogenous antioxidants, which also rescue mitochondrial anomalies caused by proteotoxic alpha-synuclein. These in vivo and in vitro findings reveal that the cellular stress mediated by alpha-synuclein-a pathological hallmark in PD-elicits DNA damage and activates the DNA damage response. The toxic cascade leading to DNA damage involves oxidant stress and mitochondrial dysfunction The data underscore the importance of DNA quality control for preservation of neuronal integrity and protection against neurodegenerative processes.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemistry & Molecular Biology

Gender biased neuroprotective effect of Transferrin Receptor 2 deletion in multiple models of Parkinson's disease

Chiara Milanese, Sylvia Gabriels, Sander Barnhoorn, Silvia Cerri, Ayse Ulusoy, S. V. Gornati, Daniel F. Wallace, Fabio Blandini, Donato A. Di Monte, V. Nathan Subramaniam, Pier G. Mastroberardino

Summary: Alterations in iron metabolism and accumulation are associated with the pathogenesis of Parkinson's disease. Targeting TfR2 pathway can be a potential therapeutic strategy to inhibit iron overload and PD progression, with neuroprotective effects showing sexual dimorphism.

CELL DEATH AND DIFFERENTIATION (2021)

Article Biochemistry & Molecular Biology

GBA Mutations Influence the Release and Pathological Effects of Small Extracellular Vesicles from Fibroblasts of Patients with Parkinson's Disease

Silvia Cerri, Cristina Ghezzi, Gerardo Ongari, Stefania Croce, Micol Avenali, Roberta Zangaglia, Donato A. Di Monte, Enza Maria Valente, Fabio Blandini

Summary: This study found that GCase deficiency promotes the release of EVs, leading to increased levels of phosphorylated alpha-syn inside fibroblasts from PD patients. This suggests that dysregulation of EV trafficking and mishandling of alpha-synuclein may play a role in GBA-associated PD.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Review Neurosciences

Are Lysosomes Potential Therapeutic Targets for Parkinson's Disease?

Alessandro Petese, Valentina Cesaroni, Silvia Cerri, Fabio Blandini

Summary: Parkinson's Disease (PD) is a common neurodegenerative disorder characterized by lysosomal dysfunction and aggregation of alpha-synuclein protein. Modulating lysosomal pathways may offer a novel approach for PD treatment.

CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2022)

Review Biochemistry & Molecular Biology

Synaptic effects of ethanol on striatal circuitry: therapeutic implications for dystonia

Paola Imbriani, Giuseppe Sciamanna, Ilham El Atiallah, Silvia Cerri, Ellen J. Hess, Antonio Pisani

Summary: Alcohol consumption affects motor behavior and control, but the therapeutic mechanism for movement disorders like myoclonus-dystonia remains unclear, with few systematic trials on GABA drugs mimicking alcohol effects. This survey aims to summarize the impact of EtOH on striatal function and provide a mechanistic explanation for alcohol-responsive movement disorders, suggesting potential drug repositioning based on different hypotheses.

FEBS JOURNAL (2022)

Article Cell Biology

The transcription factor BCL11A defines distinct subsets of midbrain dopaminergic neurons

Marianna Tolve, Ayse Ulusoy, Nikolaos Patikas, K. Ushna S. Islam, Gabriela O. Bodea, Ece Oeztuerk, Bianca Broske, Astrid Mentani, Antonia Wagener, Karen M. J. van Loo, Stefan Britsch, Pengtao Liu, Walid T. Khaled, Emmanouil Metzakopian, Stephan L. Baader, Donato A. Di Monte, Sandra Blaess

Summary: The transcription factor BCL11A is expressed in subsets of murine and human dopamine neurons, forming specific subcircuits within the dopamine system. These Bcl11a-expressing neurons are vulnerable to neurodegeneration, as inactivation of Bcl11a increases susceptibility and results in motor behavior deficits. BCL11A is crucial for establishing and maintaining the physiological characteristics of dopamine neuron subpopulations.

CELL REPORTS (2021)

Article Physiology

Effects of Circadian Phase Tailored Light Therapy on Sleep, Mood, and Cognition in Alzheimer's Disease: Preliminary Findings in a Pivotal Study

Riccardo Cremascoli, Davide Sparasci, Gianluca Giusti, Stefania Cattaldo, Elisa Prina, Fausto Roveta, Francesco Bruno, Cristina Ghezzi, Silvia Cerri, Marta Picascia, Sara Bernini, Elena Sinforiani, Michele Terzaghi, Lorenzo Priano, Alessandro Mauro, Raffaele Manni

Summary: This study investigates the effects of light therapy on sleep quality, mood, and cognition in patients with mild/moderate Alzheimer's disease. It is shown that light therapy tailored to the individual's circadian phase can induce a circadian phase shift, improve subjective sleep quality and cognitive performance, and shorten the time between dim light melatonin onset and falling asleep.

FRONTIERS IN PHYSIOLOGY (2022)

Article Clinical Neurology

Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote alpha-synuclein aggregation

Celine Galvagnion, Frederik Ravnkilde Marlet, Silvia Cerri, Anthony H. Schapira, Fabio Blandini, Donato A. Di Monte

Summary: This study found that mutations of the glucocerebrosidase 1 (GBA) gene, a prevalent risk factor for Parkinson's disease, led to altered lipid membrane composition in Parkinson fibroblasts. The altered lipid profile featured increased levels of sphingolipids and shorter-chain sphingolipid molecules. The extent of this alteration was correlated with the reduction of fibroblast glucocerebrosidase activity and accelerated alpha-synuclein aggregation. Treatment with a small molecule chaperone, ambroxol, restored the lipid profile and reversed the pro-aggregation effect. These findings suggest that the GBA mutation and consequent loss of enzymatic activity are associated with a distinct membrane lipid profile, which may increase the risk for alpha-synuclein aggregate pathology.
Article Clinical Neurology

Alpha-Synuclein is Involved in DYT1 Dystonia Striatal Synaptic Dysfunction

Giulia Ponterio, Gaia Faustini, Ilham El Atiallah, Giuseppe Sciamanna, Maria Meringolo, Annalisa Tassone, Paola Imbriani, Silvia Cerri, Giuseppina Martella, Paola Bonsi, Arianna Bellucci, Antonio Pisani

Summary: This study reveals the relationship between TA and alpha-Syn and demonstrates that alterations in alpha-Syn and SNAREs characterize the synaptic dysfunction underlying DYT1 dystonia.

MOVEMENT DISORDERS (2022)

Article Neurosciences

The proSAAS Chaperone Provides Neuroprotection and Attenuates Transsynaptic α-Synuclein Spread in Rodent Models of Parkinson's Disease

Iris Lindberg, Zhan Shu, Hoa Lam, Michael Helwig, Nur Yucer, Alexander Laperle, Clive N. Svendsen, Donato A. Di Monte, Nigel T. Maidment

Summary: The study demonstrates that proSAAS chaperone is effective in reducing motor deficits and neuronal damage caused by aSyn in Parkinson's disease, and can block the transsynaptic spread of aSyn.

JOURNAL OF PARKINSONS DISEASE (2022)

Article Multidisciplinary Sciences

Neuronal hyperactivity-induced oxidant stress promotes in vivo α-synuclein brain spreading

Michael Helwig, Ayse Ulusoy, Angela Rollar, Sinead A. O'Sullivan, Shirley S. L. Lee, Helia Aboutalebi, Rita Pinto-Costa, Benjamin Jevans, Michael Klinkenberg, Donato A. Di Monte

Summary: This study revealed the influence of neuronal activity on the transfer of alpha-synuclein, with hyperactivity enhancing protein transfer and hypoactivity attenuating it. High neuronal activity exacerbated oxidative and nitrative reactions, leading to nitration of alpha-synuclein and increased protein aggregation. Mitochondria were identified as key targets and potential sources of reactive oxygen and nitrogen species within hyperactive neurons.

SCIENCE ADVANCES (2022)

Article Neurosciences

Relevance of Biochemical Deep Phenotyping for a Personalised Approach to Parkinson?s Disease

Claudio Giuliano, Silvia Cerri, Valentina Cesaroni, Fabio Blandini

Summary: Parkinson's disease (PD) is a degenerative disorder characterized by the loss of dopaminergic neurons in the brain. The search for disease-modifying therapies for PD has been challenging due to the heterogeneity of patients and the lack of approved drugs. Stratification of PD patients based on their expected response to targeted drugs and biochemical phenotyping is a promising approach for clinical trials. Various studies have proposed biochemical characterizations of PD cohorts using different biological samples, with a focus on biomarkers such as α-synuclein and neurofilament light chain. Although still in its early stages, deep phenotyping of PD patients has the potential to identify homogeneous subgroups for tailored therapies and improve therapeutic outcomes.

NEUROSCIENCE (2023)

Article Cell Biology

Interneuronal In Vivo Transfer of Synaptic Proteins

Michael Klinkenberg, Michael Helwig, Rita Pinto-Costa, Angela Rollar, Raffaella Rusconi, Donato A. Di Monte, Ayse Ulusoy

Summary: Neuron-to-neuron transfer of pathogenic alpha-synuclein is likely relevant to Parkinson's disease development, and the spreading ability of alpha-synuclein can be reproduced by injecting AAV vectors encoding for alpha-synuclein into the mouse vagus nerve. This study investigated whether other proteins share this spreading ability. Results showed that beta-synuclein, but not VAMP2 or SNAP25, can spread to more frontal brain regions, and protein aggregation may be involved in this spreading mechanism.
Article Biochemistry & Molecular Biology

Investigation and Comparison of Active and Passive Encapsulation Methods for Loading Proteins into Liposomes

Silvia Pisani, Deborah Di Martino, Silvia Cerri, Ida Genta, Rossella Dorati, Giulia Bertino, Marco Benazzo, Bice Conti

Summary: In this study, four different active encapsulation methods were compared for loading a model protein into liposomes. Electroporation yielded the highest encapsulation efficiency, but led to a significant increase in liposome size. Freeze-thawing was an effective method, allowing for high encapsulation efficiency while maintaining suitable size. Charged liposomes showed slower in vitro release and good cytocompatibility.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Review Pharmacology & Pharmacy

Dyskinesia and Parkinson's disease: animal model, drug targets, and agents in preclinical testing

Valentina Cesaroni, Fabio Blandini, Silvia Cerri

Summary: LIDs are supported by complex molecular and neurobiological mechanisms that are still being studied today. This complexity suggests the need of developing personalized pharmacological approach to obtain an effective amelioration of LID condition and improve the quality of life of PD patients.

EXPERT OPINION ON THERAPEUTIC TARGETS (2022)

暂无数据